Bound by bone : a look at fibrodysplasia ossificans progressiva : an honors thesis (HONRS 499) by Bassler, Pacita M.
Fibrodysplasia Ossificans Progressiva 1 
Bound by Bone: A Look at 
Fibrodysplasia Ossificans Progressiva 
An Honors Thesis (HONRS 499) 
by 
Pacita M. Bassler 
Thesis Advisor 
(Dr. Renee Twibell) 
Ball State University 
Muncie, IN 
October 2002 
December 15, 2002 
Fibrodysplasia Ossificans Progressiva 2 
Abstract 
Fibrodysplasia Ossificans Progressiva, also known as FOP, is a devastating and 
debilitating genetic disease characterized by the formation of heterotopic bone. By 
exploring the pathophysiology, current treatments, and recent research we take an 
in-depth look at this rare and unfamiliar disease. Through application of the 
nursing process, nursing care of patients affected with FOP is discussed in the second 
half of the paper. Even though this is an incredibly rare disease, awareness 
regarding FOP needs to be brought to the forefront. Knowledge is power. Only 
through education can people be armed with the knowledge needed to take proper 
care of a person affected with Fibrodysplasia Ossificans Progressiva. 
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A young couple take their three year-old son into the doctor's office. They are 
concerned about the painful, warm, red mass that has appeared on his back. The 
mass frrst appeared approximately twelve hours ago and was originally dime-sized. It 
is now the size of a grapefruit. 
A thirty year-old female wheels around the mall in her motorized wheelchair. 
Two years earlier she became confined to her wheelchair after tripping in her 
house. Both her hips are fused and permanently intmobile. While her right arm is 
free to move, her left arm is frozen in a right angle to her side. 
What do these two people have in common? They both are afflicted with a 
disease known as Fibrodysplasia Ossificans Progressiva, or FOP. FOP is an extremely 
rare genetic disorder characterized by excessive bone formation. Until recently, 
there has not been any research performed on this extraordinary and devastating 
disease. 
Overview 
Fibrodysplasia Ossificans Progressiva, formerly known as Myositis Ossificans 
Progressiva, is a rare genetic disorder characterized by the formation of heterotopic 
bone. FOP literally means "soft, connective tissue that progressively turns to bone." 
(Wagman, Kantanie, & Kaplan, 2(01) 
Pathophysiology 
In FOP, heterotopic ossification occurs. This means that bone forms where 
bone does not belong, such as in the elbow or hip joints. This bone is "normal" bone; 
the abnormality is not the bone but its timing and location of formation. 
Microscopically, this bone is identical to "normal" bone. On an x-ray, the bone 
appears as "normal" bone. lf this bone breaks, it repairs itself as "normal" bone 
does. Just like "normal" bone, this bone even contains marrow. (Maeder, 1998) As 
this extra bone continues to form, it eventually makes a "second skeleton." 
The formation of the bone is unpredictable in its rate and severity. It affects 
each individual differently. The one common denominator between FOP patients is 
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the predictable pattern; the anatomic progression is strikingly similar among each 
individual. (Treatment Considerations, 2001; Lynch, 1999) Formation of the bone is 
not random, but mirrors skeletal formation beginning in the womb. The heterotopic 
ossification process follows the same pattern as in embryonic skeletal development: 
cephalocaudal and proximal-distal. The ossification begins with the connective 
tissue in the neck and spine. It next affects the shoulders followed by the hips and 
elbows. Knees and wrists are affected next then the ankles. Lastly, the jaw becomes 
ossified. (Maeder, 1998) Fortunately, the muscles of the diaphragm and heart are not 
affected. Because of this similar pattern of bone formation, the body is in essence not 
just forming extra bone but rather a "second skeleton." This "second skeleton" 
eventually binds the individual in bone, leading to ankylOSiS and complete 
immobility. (Treatment Considerations, 2(01) 
As mentioned previously, heterotopic ossification follows a specific pattern 
but the rate at which it progresses and its severity for each individual differ. A 
flare-up is when FOP exacerbates and usually involves the presence of a lesion. This 
is when ossification of the bone actively occurs. These flare-ups are sporadic and 
unpredictable. A person may go months or years without experiencing a flare-up. 
When an individual experiences a flare-up, it is impossible to predict the duration or 
severity. Flare-ups usually occur as a result of some type of trauma to the body. The 
trauma can be as severe as a fall or as minor as an intramuscular injection during a 
routine vaccination. In fibrodysplasia ossificans progressiva, any type of trauma to 
the body, no matter how minor, can trigger a sudden flare-up. Flare-ups can also 
occur spontaneously and at random with no precipitating factor. A person can go to 
bed one night able to walk and wake up the next morning permanently bound to a 
wheelchair. At this point in time, it is unclear why this disease is active at times and 
why it lies dormant at other times. (Treatment Considerations, 2001; Wagman, 
Kantanie, & Kaplan, 2001) 
It is still a mystery as to why this bone decides to for, although through 
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research there have been a number of discoveries that may eventually lead to a 
definitive answer as to why this bone forms. In the body, bone formation occurs in 
one of two ways: intramembranous formation or endochondral formation. In 
intramembranous formation bone cells called osteobIasts secrete a bony substance on 
top of the bone. This is similar to bricklayers stacking bricks to build a wall. This 
type of formation is what causes the shaft of the long bones to widen and the top of 
the skull to thicken. Endochondral formation is how the bones grow longer and how 
fractures heal. In this process, the body forms a cartilage model. Consequently, it is 
infiltrated, reabsorbed, and replaced by bone. An example of this bone formation 
occurs when the fetal skeleton develops. In the disease process of FOP, heterotopic 
bone forms using the endochondral pathway. (Maeder, 1998) 
Why does heterotopic bone form in patients with FOP? Researchers have 
stumbled across a few reasons why the progressive growth of bone, known as 
heterotopic ossification, occurs in FOP patients. One reason involves bone-producing 
proteins called bone morphogenetic proteins, or BMPs. In FOP, researchers 
specifically look at BMP4, a master protein involved in the formation of the skeleton. 
(Wagman, Kantanie, & Kaplan, 2(01) The "normal" job of BMP is to create bone 
during embryonic development. (Lynch, 1999) In patients with FOP, BMP production 
is excessive. The overproduction of BMP, specifically BMP4, causes heterotopic 
ossification. (Tenth Annual, 2001; Lynch, 1999) It has been discovered that the 
lymphocytes in FOP patients carry the bone-producing protein BMP4. Normally this 
protein is not found in lymphocytes. The presence of BMP4 in the lymphocytes 
highly suggests why bone formation occurs easily after an injury. When an injury 
or trauma to an area occurs, lymphocytes "swarm to the site" with their doses of 
BMP4 causing ossification at the site. (Maeder, 1998) It is this inappropriate 
expression of BMP4 that causes heterotopic ossification. (Tenth Annual, 2(01) Under 
"normal" conditions, there are "safety switches" to tell the body to stop producing 
BMP4. So, if a cell where even to begin producing the bone-producing protein, the 
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body would halt the process of bone formation before it occurs. (Tenth Annual, 2001) 
Cells of an FOP patient are unable to react appropriately to the increased presence of 
BMP; there is a disturbance between BMP4 and its antagonists. (Tenth Annual, 2001) 
Researchers have recently discovered Noggin, a protein involved in the 
regulation of the concentrations of BMP4 available to the body. (Tenth Annual, 2001) 
Initially the discovery of Noggin held much promise in finding the real cause of 
heterotopic ossification. Noggin works by actively binding to BMP4 and inactivating 
it. (Tenth Annual, 2001) It was hypothesized that there must be a malfunction in the 
expression of this protein. Later, it was discovered that there were no mutations 
found in the Noggin gene. (Tenth Annual, 2001) Even though this was a 
disappointment, Noggin still holds promise in helping to fmd a cure for FOP. In 
essence, FOP patients have lymphocytes that over express BMP4 while simultaneously 
under expressing the proteins that block and suppress BMP4. (Treatment 
Considerations, 2001) 
Angiogenesis plays an important role in the formation of heterotopic bone. 
Scientists have recently discovered the overproduction of basic fibroblast growth 
factor during FOP flare-ups. It is circulated in the blood and excreted in the urine. 
This protein stimulates the production of new blood vessels (angiogenesis) during 
flare-ups. (Tenth Annual, 2001; Wagman, Kantanie, & Kaplan, 2001) One important 
factor of bone formation is adequate blood supply. Identifying the presence of this 
protein during flare-ups holds promising treatments in the future. Current 
treatment research is now focusing on this aspect of FOP. 
Another important factor to consider with FOP is the presence of mast cells. 
Mast cells are intimately involved during the flare-ups associated with FOP. (Tenth 
Annual, 2001) It has been found that there is an abundance of mast cells present at 
every stage of the disease process. (Treatment Considerations, 2001) At this time, it is 
unknown of the exact part mast cells play in the heterotopic ossification process. It 
is believed that they playa very important role is the disease process of FOP. 
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Scientists hypothesize a possible autoimmune component to the disease. Researchers 
are beginning to explore the possibilities of the possible role of the immune system 
in FOP. (Tenth Annual, 2001) 
Etiology 
FOP is an autosomal dominant genetic disorder. This means that a person who 
carries the FOP gene will express the gene; the person will have FOP. (Wagman, 
Kantanie, & Kaplan, 2001) In 1998, it was identified that the location of the gene was 
on the long arm of chromosome four. This discovery will make it easier to pinpoint 
the exact location of the FOP gene someday down the road. (Tenth Annual, 2001) A 
person who carries the gene for FOP has a 50% chance of passing the trait on to 
his/her offspring. (Wagman, Kantanie, & Kaplan, 2001) Presently, there are three 
families in the world known to have the gene and passed it on to offspring. (Maeder, 
1998) Almost all known cases of FOP have resulted from the spontaneous mutation in 
the gene. (Wagman, Kantanie, & Kaplan, 2001; Maeder, 1998) 
Incidence/Prevalence 
Fibrodysplasia Ossificans Progressiva affects an estimated 1 in 2 million, or 
2,500, people worldwide. (Wagman, Kantanie, & Kaplan, 2001; Lynch, 1999) To date, 
researchers are aware of fewer than two hundred cases throughout the world. 
(Wagman, Kantanie, & Kaplan, 2001) It affects both men and women, both young and 
old. Symptoms of FOP usually appear within the first or second decade of life; most 
people know that they are affected with FOP by the age of ten. (Wagman, Kantanie, & 
Kaplan, 2001) 
Assessment 
Physically, there are two similar features of FOP patients: the malformation of 
the great toes and heterotopic ossification later in life. (Wagman, Kantanie, & 
Kaplan, 2001) The malformation of the great toes acts as a very early warning sign 
of FOP prior to the onset of heterotopic ossification. (Wagman, Kantanie, & Kaplan, 
2001) At birth, children appear "normal" except for a congenital malformation of 
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the great toes. The great toes are generally small and misshapen. The toe may be 
turned inward and the joint is often missing. (Lynch, 1999) There is a very small 
percentage of FOP patients who do not have the congenital malformation of the great 
toes at birth. These children demonstrated arthritic-like changes in their toes by the 
age of ten. (Wagman, Kantanie, & Kaplan, 2(01) 
The heterotopic ossification process in these patients often begins with a 
"flare-up." Flare-ups typically mark the beginning of the bone formation process 
and may last as long as 6-8 weeks until the bone is completely formed. (Wagman, 
Kantanie, & Kaplan, 2001) These flare-ups are often painful; the pain usually 
subsides once it is over. (Wagman, Kantanie, & Kaplan, 2(01) FOP is not chronically 
painful. (Wagman, Kantanie, & Kaplan, 2(01) The formation of lesions usually 
characterize the flare-up process. In a flare-up, the affected area becomes swollen, 
red, hot, and painful. Within days or weeks, this area turns to bone. (Wagman, 
Kantanie, & Kaplan, 2001; Maeder, 19984) This is the process known as heterotopic 
ossification. As mentioned previously, these lesions are painful. After the lesion has 
developed into bone, they no longer hurt although they may still be a source of 
discomfort to the person due to excessive pressure in the area of bone formation. 
(Wagman, Kantanie, & Kaplan, 2001) 
An initial flare-up is often misdiagnosed as a tumor. The leSions, in their 
intermediate stage, are microscopically indistinguishable from a type of tumor called 
juvenile fibromatosis. (Treatment Considerations, 2(01) This can lead to devastating 
effects. Attempting to remove the lesion or bone results in even more aggressive 
bone formation. (Wagman, Kantanie, & Kaplan, 2001) 
Flare-ups tend to differ slightly in adults and in children. While children tend 
to have nodular flare-ups characterized by distinct leSions, adults tend to have a more 
"sheet-like" flare-up. In other words, adults tend to have swelling occurring in the 
entire limb instead of in the form of a lesion. Even though there is a tendency for 
one type of flare-up to occur during a certain age, either form of a flare-up can 
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occur at any age. (Wagman, Kantanie, & Kaplan, 2001) Eventually, as a result of 
multiple flare-ups, ankylosis occurs rendering movement impossible. (Treatment 
Considerations, 2001; Lynch, 1999) People affected with FOP may end up fused in a 
standing position or in a twisted sitting position. (Maeder,I998) There is no way of 
knowing how a person will be "locked" for an eternity. Most FOP patients are 
confined to a wheelchair by the time they are in their early twenties. (Treatment 
Considerations, 2001) 
FOP is not a fatal disease in itself, but it can cause fatal complications for those 
affected with the disease. One life threatening complication of FOP is the effects of 
heterotopic ossification on the chest wall. The chest wall eventually has grids of 
bone that can restrict breathing. The severe restrictions on the chest wall places the 
patients at an increased risk for cardiopulmonary problems. Cardiopulmonary 
complications are believed to playa major role in the shortened lifespan of some FOP 
patients. Another life threatening complication occurs when the jaw fuses. This can 
result in severe malnutrition and in some cases starvation. (Treatment 
Considerations, 2001; Wagman, Kantanie, & Kaplan, 2001; Lynch, 1999; Maeder, 1998) 
Despite these horrific complications, there are muscles that are fortunately spared 
from heterotopic ossification. This includes the diaphragm, the heart, the tongue, 
the eyes, and the face. (Wagman, Kantanie, & Kaplan, 2001) Another common feature 
of FOP among patients is conductive hearing impairment. At this point in time it is a 
poorly-understood problem associated with the disease. (Treatment Considerations, 
2001) 
"One feature that marks victims of FOP, one that strikes everyone who meets 
them, is their ability to take the unbearable in stride." (Maeder, 1998) FOP is a disease 
that obviously can have some psychosocial ramifications. All people adapt 
differently. Children who are affected by FOP themselves tend to cope better than 
their parents. (Wagman, Kantanie, & Kaplan, 2001) It has also been noted that the 
earlier a child is affected with the physical symptoms and limitations of FOP, the 
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easier it is for the child to cope psychologically with the physical restrictions 
imposed on them. (Wagman, Kantanie, & Kaplan, 2001) Resources that are useful for 
patients, parents, family, and friends include: professional guidance, family 
counseling, and meeting/writing with other members of the FOP community. 
(Wagman, Kantanie, & Kaplan, 2(01) 
There is no one definitive laboratory test that aides in the diagnOSis of FOP. 
Through research, it has been identified that an excessive amount of mast cells are 
present during each stage of lesional development during flare-ups. To see the mast 
cells under a microscope, a special dye must be used to identify them. (Tenth Annual, 
2(01) In the preliminary stages of research, a muscle biopsy was taken from a 
patient affected with FOP to investigate any abnormalities in the muscle tissue. Much 
to the disbelief of researchers, the muscle biopsy indicated 100% normal muscle 
tissue. Unfortunately, a month after the biopsy, bone regrew in its place. (Skeleton 
Key, 1999) 
Radiographic x-rays can be used as a non invasive way to show the presence 
of a lesion. In early lesion development, the x-ray indicates only soft tissue swelling. 
Eventually, in the later stages of lesion development, the x-ray shows the new 
"normal" bone that has formed. Bone scans are another non-invasive radiographic 
technique used in FOP patients. These scans can show us formation of new bone 
early on in the course of a flare-up. (Wagman, Kantanie, & Kaplan, 2001) 
Treatment 
Presently, there is no prevention or treatment available for those affected by 
FOP; it is an incurable disease. The present treatments can be divided into two 
separate categories: symptom-modifying and disease-modifying. At this time, there 
are no disese-modifying therapies. (Wagman, Kantanie, & Kaplan, 2(01) However, 
there are ways to manage the symptoms of flare-ups and preventative measures to 
take to reduce the risk of complications and/or flare-ups associated with the disease. 
Medications for FOP are used to minimize the pain associated with flare-ups. 
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Current medications used for FOP can be classified into three classes. (Treatment 
Considerations,2(01) Class I medications are medications that have been used to treat 
the symptoms of an acute flare-up. These medications have anecdotal reports with 
favorable clinical trials. They also have minimal side effects. Examples of class I 
medications include: corticosteroids, non-steroidal anti-inflammatory drugs 
(NSAIDs), and cyclo-oxygenase 2 inhibitors (Cox-2 inhibitors). Short-term use of 
prednisone has shown to be effective in the management of symptoms during an 
acute flare-up. Prednisone decreases lymphocyte recruitment and tissue infJ.ltration. 
It is also a very potent anti-inflammatory medication. In order for prednisone to be 
effective, it must be started within 24 hours of the onset of the flare-up. The first 24 
hours corresponds with the earliest phase of acute infiltration of lymphocytes into 
the skeletal muscle. Prednisone must not be used for longer than four days. 
Prolonged use of steroids has not proven to be of any benefit and actually may help 
accelerate heterotopic ossification. Although prolonged use is contraindicated, there 
is one indication for long-term use of steroids. If the flare-up involves the 
submandibular region long-term therapy can be used. These flare-ups can be life-
threatening as it can interfere with breathing and swallowing. The use of steroids 
has not been effective in treating flare-ups involving the trunk of the body. 
(Treatment Considerations, 2001) 
Non-steroidal anti-inflammatory drugs, also known as NSAIDs, are commonly 
used in the management of symptoms during acute flare-ups. NSAlDs typically used 
include ibuprofen (Advil or Motrin) and indomethacin (Indocin). Both medications 
are helpful with the symptomatic management of FOP because of their anti-
inflammatory and anti-angiogenic properties. (Treatment Considerations, 2001) 
Cyclo-oxygenase 2 (Cox-2) inhibitors include the medications celecoxib 
(Celebrex) and rofecoxib (Vioxx). These two medications have properties much like 
the NSAIDs, except they have fewer side effects. One problem with the Cox-2 
inhibitors is that they should only be used in patients older than sixteen years of age. 
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(Treatment Considerations, 2(01) 
Class II medications are medications that theoretically apply to FOP. These 
medications have been approved for treatment in other disorders and have few side 
effects. The types of medications in this category include leukotriene inhibitors and 
mast cell stabilizers. One type of leukotriene inhibitor currently used for FOP is 
montelukast (Singulair). This medication blocks inflammatory mediators in the 
inflammatory process. It also complements the action of Cox-2 inhibitors. Cromolyn 
(Gastrocrom) is the mast cell stabilizer currently used for FOP. Mast cell stabilizers 
reduce mast cell degranulation. One disadvantage of this medication is that it is 
poorly absorbed in the gastrointestinal tract. (Treatment Considerations, 2(01) 
Class III medications are investigational drugs. These include the following 
medications: Thalidomide, Squalamine, and Noggin. Thalidomide has anti-angiogenic 
properties and is also an immuno-modulator. Squalamine also possess anti-
angiogenic properties. Noggin works by blocking the action of BMP4. (Treatment 
Considerations, 2(01) 
Iontophoresis is a treatment currently being explored in the management of 
FOP symptoms. It involves using electrodes at a low electrical current to deliver 
medication deep into muscle tissue. One combination of medication used in this 
treatment is a steroid called dexamethasone and a local anesthetic called lidocaine. By 
delivering these medications deep into the muscle tissue, many patients have found 
relief from the pain associated with flare-ups. There is no evidence at this time that 
supports the fact that this treatment will change the course of the disease. It does 
however provide pain relief. (Wagman, Kantanie, & Kaplan, 2(01) 
Many people wonder if the extra bone that forms can be removed surgically. 
The answer is yes, it can, but with severe consequences. This is traditionally not an 
option for FOP patients. By removing the extra bone with surgery, more trauma is 
caused to the area and more extensive bone growth results. (Wagman, Kantanie, & 
Kaplan, 2(01) 
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Injury prevention plays a big role in the management of FOP. By preventing 
injury and trauma to the tissues, many flare-ups can be avoided. Intramuscular 
injections should be avoided. By injecting a needle directly into the muscle, trauma 
to the tissue results. Even though this is a minor "trauma," in people with FOP it can 
lead to a painful flare-up. Other types of injections are tolerated fine with FOP 
patients. People affected with FOP should also receive annual flu shots administered 
subcutaneously. By receiving a flu shot, the chances of having the flu during flu 
season are greatly decreased. In patients who have restricted chest wall expansion, a 
flu shot could save his/her life. Avoiding any type of activity that has a high risk 
for injury is recommended. Contact sports should not even be considered because of 
the devastating outcomes that can occur. (Wagman, Kantanie, & Kaplan, 2001) 
Unfortunately, physical therapy is contraindicated in people with FOP. It does 
not help in maintaining joint movement. In fact, extensive physical therapy can 
actually lead to a painful flare-up. Active range of motion is okay and should be 
encouraged. (Wagman, Kantanie, & Kaplan, 2001) 
Recent Research 
Research in the area of FOP is extensive at this time. Many people are putting 
a lot of time and effort to not only find an effective treatment for FOP but also a cure. 
Gene therapy and gene correction are an evolving technology. Researchers 
are considering this as a possible cure for FOP one day. It is too early to tell if this 
would be an effective treatment someday. There is still a lot of work and research 
that have to occur in the development of gene therapy in general before applying it 
specifically to a disease such as FOP. Scientists still feel that one day gene therapy 
and gene correction with the use of the protein Noggin may provide a viable option. 
(Treatment Considerations, 2001; Tenth Annual, 2001) 
Advances in today's research suggest that the use of stem cells may hold the 
key to a cure for FOP. This is an area that has not had much physical application in 
research but theoretically it holds promising results. (Treatment Considerations, 
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2001) 
Cyclo-oxygenase 2 inhibitors are currently used in the symptomatic treatment 
of FOP during acute flare-ups. Current data suggests that with protaglandin 
inhibitors such as Cox-2 inhibitors heterotopic ossification can be prevented. For 
these prostaglandin inhibitors to be effective in preventing the formation of bone, 
the medication must be at a certain level in the blood before the onset of a flare-up. 
This is an area to continue to look into for the prevention of bone formation in FOP 
patients. (Treatment Considerations, 2001) 
Anti-angiogenic agents are medications that inhibit new vessel formation 
(angiogenesis). Angiogenesis is a major contributor to lesion formation and 
heterotopic ossification. Researchers believe if they can inhibit the growth of the 
new blood vessels, then they can stop the process of heterotopic ossification. 
Theoretically this is true. Presently, there are a number of anti-angiogenic agents 
being researched for their uses in the FOP disease process. One is called Squalamine. 
Discovered by accident by Dr. Michael Zasloff in 1992, Squalamine expresses potent 
anti-angiogenic properties. It is anticipated that this agent will target the early and 
sever pre-osseous flare-ups. At this point in time there is no absolute guarantee that 
squalamine will be an effective treatment for FOP, but there is hope. (Treatment 
ConSiderations, 2001; Tenth Annual, 2001) 
ThalidOmide is another anti-angiogenic agent currently under research for 
FOP because of its angiogenic properties. In Europe in the 1950's, it was used as a 
sedative. It was generally tolerated well by patients. Then, in 1961, birth defects 
were reported. These birth defects were eventually linked to thalidomide. The birth 
defects, which included various defects of the limbs, were due to the inhibition of 
angiogensis during fetal skeletal formation. Thalidomide inhibits fibroblast growth 
factor which induces the formation of blood vessels. It is also an immune-modulator. 
This means that it controls reactions of the immune system and it could possibly play 
a role during the early development of FOP lesions when the lymphocytes attack the 
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muscle tissue forming bone. In August 1998, phase I of the thalidomide trial began. 
(Treatment Considerations, 2001; Tenth Annual, 2001) The primary objective of this 
study was to "determine the potential efficacy of thalidomide during active disabling 
flare-ups, while evaluating duration, intensity, and frequency of flare-ups." (Tenth 
Annual, 2001) While the study is ongoing, there is preliminary data available. By 
January 2001, there were 15 FOP patients involved in the study. The flare-ups 
continued with all patients taking thalidomide; however, patients and/or their 
parents reported that there was an improvement in the duration and severity of the 
flare-ups in 14 out of 15 of the patients. Since January 2001, seven patients had 
received their second annual bone scan. Of those seven, six showed no new site of 
heterotopic bone formation when compared to the initial bone scan at the beginning 
of the study. While the thalidomide trial continues and no definite results have been 
reported, this study has very promising preliminary data. (Treatment 
Considerations, 2001; Tenth Annual, 2001) 
Retinoids are another area of interest for researchers searching for a 
treatment and cure for FOP. These agents are of interest because of their ability to 
differentiate connective tissue into cartilage and bone. A specific agent researchers 
have been looking into is Accutane, also known as isotretinoin or 13-cis retinoic acid. 
This medication is traditionally used in the treatment of severe acne. It is 
contraindicated in pregnant women because of the effects it has on the fetal 
skeleton. A clinical trial was conducted between 1984 and 1988 at the National 
Institutes of Health (NIH). Results indicated that growth of bone that had already 
began forming was not halted. It did appear to decrease new episodes of bone 
formation around joints by at least 27%. This study also indicated that isotretinoin 
had some unpleasant side effects. This agent is not a cure, but it can offer some 
beneficial results for those who decide to take it. (Treatment Considerations, 2001; 
Wagman, Kantanie, & Kaplan, 2001) 
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Conclusion 
Fibrodysplasia Ossificans Progressiva is a rare devastating and debilitating 
disease. Even though it physically affects fewer than 200 known people worldwide, it 
also affects those family and friends who can only sit around as the person 
eventually becomes bound within his/her own skeleton. Therefore, a treatment and 
cure is needed. There are a small number of scientists and researchers dedicated to 
finding a cure for this genetic disorder. Hopefully one day we can learn how to 
prevent and treat these patients and free them from their skeletal prison. 
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Nursing Diagnosis: Impaired Physical Mobility related to decreased strength and endurance secondary to 
musculoskeletal impairment. 
Expected Outcomes 
• Demonstrate use of adaptive 
equipment to increase 
mobility. 
• Use safety measures to 
minimize potential for injury. 
Interyentions 
• Instruct patient how to use 
assistive devices (i.e. walker, 
bath bench, bedside commode, 
etc.) correctly . 
• Educate patient about 
appropriate safety measures to 
decrease risk for injury . 
• Encourage active range of 
motion exercises. 
Rationale 
• Passive range of motion 
exercises are contraindicated 
for patients with FOP. 
• Physical therapy is 
contraindicated for patients 
with FOP. 
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Nursing Diagnosis: Pain, acute, related to tissue trauma secondary to lesions associated with FOP. 
Expected Outcomes 
• Patient will state a decrease in 
pain. 
Interyentions 
• Administer prescribed 
medications, such as NSAlDs or 
Cox-2 inhibitors, for pain. 
• Position patient for comfort. 
• Acknowledge client's 
complaint of pain as real. 
• Encourage patient to use a 
whirlpool on a gentle cycle 
during flare-ups. 
Rationale 
• Warm water of a whirlpool 
helps with ease the pain 
associated with flare-ups. 
• Using whirlpool on a gentle 
cycle helps to prevent 
injury/trauma to tissues 
leading to a second flare-up. 
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Nursing Diagnosis: Ineffective Breathing Pattern related to immobility secondary to decreased chest wall 
expansion. 
Expected Outcomes 
• Patient will achieve maximum 
pulmonary function. 
• Patient will remain free from 
respiratory illness. 
• Patient will maintain 
respiratory rate within normal 
limits. 
• Patient will maintain ABGs 
within normal limits. 
Interyentions 
• Encourage deep breathing. 
• Encourage patient to receive 
annual influenza vaccine 
(subcutaneously) during the 
flu season. 
• Assess respiratory rate 
frequently. 
• Monitor for abnormal ABGs 
and notify physician if values 
are abnormal. 
Rationale 
• Receiving an influenza 
vaccine will decrease 
complications of respiratory 
illness. 
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Nursing Diagnosis: Risk for Injury related to altered mobility secondary to Fibrodysplasia Ossificans Progressiva. 
Expected Outcomes 
• Patient will remain free from 
injury. 
• Patient will implement safety 
measures to prevent falls and 
other injuries. 
• Patient will identify factors 
that increase risk for injury. 
Interyentions 
• Instruct patient to remove or 
decrease obstacles at home (i.e. 
throw rugs, clutter, etc.) that 
will increase the risk of 
injury. 
• Educate patient about correct 
way to use assistive devices. 
Rationale 
• If a patient knows the correct 
way to use an assistive device, 
then he/she will be at a 
decreased risk of injuring 
himself/herself while using 
the device. 
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Nursing Diagnosis: Impaired Skin Integrity related to the effects of pressure and/or immobility secondary to 
motor deficits. 
Expected Outcomes 
• Patient will identify causative 
factors for skin breakdown. 
• Patient will notify care giver if 
change of position is needed. 
• Patient will remain free from 
pressure ulcers. 
Interyentions 
• Assess skin frequently for 
signs and symptoms of skin 
breakdown. 
• Reposition patient frequently 
(every two hours) and as 
needed. 
• Keep moist areas (i.e. skin 
creases) dry. 
• Place proper padding over any 
bony prominences. 
• Implement wound care 
protocol or notify enterostomal 
nurse if pressure ulcer 
develops. 
Rationale 
• Keeping moist areas dry will 
promote skin to stay intact. 
• Repositioning prevents 
excessive pressure to one area. 
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Nursing Diagnosis: Altered Nutrition: Less than Body Requirements related to the inability to chew. 
Expected Outcomes 
• Patient will maintain body 
weight. 
• Patient will demonstrate no 
signs or symptoms of 
malnourishment or 
dehydration (i.e. dry skin, 
brittle nails, thin hair,dry 
mucous membranes, poor skin 
turgor, etc.). 
• Patient will verbalize food 
choices that are nutrient 
dense. 
• Patient will identify foods that 
are easily eaten with a fused 
jaw. 
Interyentions 
• Encourage patient to eat small 
frequent meals and snacks 
throughout the day. 
• Teach patient about nutrient 
dense foods. 
• Encourage patient to use 
dietary supplements (i.e. 
Ensure) as needed. 
• Discuss with patient foods that 
are easy to ingest or how to 
prepare foods that are easy to 
ingest with a fused jaw. 
• Encourage adequate oral fluid 
intake. 
• Administer intravenous fluids 
as prescribed by physician. 
Rationale 
• Eating small frequent meals 
and snacks throughout the day 
will help increase caloric 
intake. 
• Nutrient dense foods will 
decrease risk of malnutrition. 
• Dietary supplements can help 
in meeting adequate caloric 
needs. 
• Knowing what foods that are 
easy to eat will encourage 
adequate nutrition. 
• Adequate oral fluid intake will 
help prevent dehydration. 
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Nursing Diagnosis: Body Image Disturbance related to changes in appearance secondary to chronic disease. 
Expected Outcomes 
• Patient will verbalize and 
demonstrate acceptance of 
appearance. 
Interyentions 
• Encourage independence. 
• Provide anticipatory guidance 




• Independence will give the 
patient the self-confidence 
needed to accept themselves. 
• Providing anticipatory 
guidance about the disease 
process will give them the 
insight as what to expect and 
plan for in the upcoming 
years. 
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